Renalytix PLC (LSE: RENX) is a precision diagnostics company developing AI-driven kidney health tests. Its KidneyIntelX platform predicts disease progression in early-stage CKD patients, helping physicians tailor treatment. Despite regulatory and commercial challenges, Renalytix plays in a high-need space, and success could reshape how chronic kidney disease is managed.
差價合約 (CFD) 是一種複雜的金融工具，利用槓桿交易雖然可能放大收益，但同樣也會加劇虧損風險，導致資金快速流失。數據顯示，79.58% 的散戶投資者在使用該提供商服務進行差價合約交易時出現帳戶虧損。在進行交易之前，請確保您充分了解差價合約的運作機制，並仔細評估自己是否有能力承擔資金虧損的高風險。
評級和評論
評級和評論
